CBP/P300 BRD Inhibition Reduces Neutrophil Accumulation and Activates Antitumor Immunity in TNBC.
Xueying YuanXiaoxin HaoHilda L ChanNa ZhaoDiego A PedrozaFengshuo LiuKang LeAlex J SmithSebastian J CalderonNadia LieuMichael J SothPhilip JonesXiang H F ZhangJeffrey M RosenPublished in: bioRxiv : the preprint server for biology (2024)
In neutrophil-enriched triple-negative breast cancer (TNBC) models, CREB binding protein (CBP)/P300 bromodomain (BRD) inhibition reduces tumor growth and systemic neutrophil accumulation while stimulating an antitumor immune response. This improves standard-of-care therapies, suggesting a potential therapeutic benefit of CBP/P300 BRD inhibitors for neutrophil-enriched TNBC.